Koers ImmunoPrecise Antibodies Ltd. Toronto S.E.
Aandelen
IPA
CA45257F2008
Farmaceutische producten
Omzet 2024 * | 24,59 mln. 17,97 mln. 16,82 mln. | Omzet 2025 * | 29,82 mln. 21,8 mln. 20,4 mln. | Marktkapitalisatie | 47,55 mln. 34,76 mln. 32,53 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -8,77 mln. -8,21 mln. | Nettowinst (verlies) 2025 * | -9 mln. -6,58 mln. -6,16 mln. | EV/omzet 2024 * | 1,93 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,59 x |
K/w-verhouding 2024 * |
-3,76
x | K/w-verhouding 2025 * |
-5,1
x | Werknemers | 102 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,41% |
Recentste transcriptie over ImmunoPrecise Antibodies Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
-9,14% | 11,95 mld. | |
+5,24% | 8,71 mld. | |
-8,42% | 8,12 mld. |